Cortisol response to low dose versus standard dose (back-to-back) adrenocorticotrophic stimulation tests in children and young adults with thalassemia major.

Soliman AT, Soliman AT, Yassin M, Majuid NM, Sabt A, Abdulrahman MO, De Sanctis V

Indian journal of endocrinology and metabolism1 Nov 2013Cited by 21 (Europe PMC)

PMID24381882PMCIDPMC3872683DOI10.4103/2230-8210.122620PepBankPUB-24381882

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study15

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone15

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

01HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, low-dose testing identified adrenal insufficiency in 8 patients (34.7%) using a 550 nmol/L peak cutoff and 200 μg increment above baseline.
In plain wordsIn thalassemia patients, the low-dose test identified adrenal insufficiency in 34.7% at the 550 nmol/L cutoff.
Peptide
Cosyntropin
Outcome
Not applicableAdrenal insufficiency at 550 nmol/L cutoff, low dose
Study
n = 23
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Adrenal insufficiency
8 patients
low-dose test, 550 nmol/L peak cutoff
Adrenal insufficiency proportion
34.7%
low-dose test, 550 nmol/L peak cutoff
Source sentences
Summary
Using a peak total cortisol cutoff level of 550 nmol/L and increments of 200 μg above basal cortisol, adrenal insufficiency (AI) was demonstrated in 8 patients (34.7%) after the LD ACTH and in 2 patients (8.7%) after SD cosyntropin (ACTH) test, but none of the controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188201
02HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, standard-dose testing identified adrenal insufficiency in 2 patients (8.7%) using a 550 nmol/L peak cutoff and 200 μg increment above baseline.
In plain wordsIn thalassemia patients, the standard-dose test identified adrenal insufficiency in 8.7% at the 550 nmol/L cutoff.
Peptide
Cosyntropin
Outcome
Not applicableAdrenal insufficiency at 550 nmol/L cutoff, standard dose
Study
n = 23
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Adrenal insufficiency
2 patients
standard-dose test, 550 nmol/L peak cutoff
Adrenal insufficiency proportion
8.7%
standard-dose test, 550 nmol/L peak cutoff
Source sentences
Summary
Using a peak total cortisol cutoff level of 550 nmol/L and increments of 200 μg above basal cortisol, adrenal insufficiency (AI) was demonstrated in 8 patients (34.7%) after the LD ACTH and in 2 patients (8.7%) after SD cosyntropin (ACTH) test, but none of the controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188202
03HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, low-dose testing identified adrenal insufficiency in 5 patients (21.7%) using a 420 nmol/L peak cutoff and 200 μg increment above baseline.
In plain wordsIn thalassemia patients, the low-dose test identified adrenal insufficiency in 21.7% at the 420 nmol/L cutoff.
Peptide
Cosyntropin
Outcome
Not applicableAdrenal insufficiency at 420 nmol/L cutoff, low dose
Study
n = 23
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Adrenal insufficiency
5 patients
low-dose test, 420 nmol/L peak cutoff
Adrenal insufficiency proportion
21.7%
low-dose test, 420 nmol/L peak cutoff
Source sentences
Summary
Using a peak total cortisol cutoff level of 420 nmol/L and increments of 200 μg above basal cortisol, AI was demonstrated in 5 patients (21.7%) after the LD ACTH and in 2 patients after SD ACTH test (8.7%), but none of controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188203
04HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, standard-dose testing identified adrenal insufficiency in 2 patients (8.7%) using a 420 nmol/L peak cutoff and 200 μg increment above baseline.
In plain wordsIn thalassemia patients, the standard-dose test identified adrenal insufficiency in 8.7% at the 420 nmol/L cutoff.
Peptide
Cosyntropin
Outcome
Not applicableAdrenal insufficiency at 420 nmol/L cutoff, standard dose
Study
n = 23
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Adrenal insufficiency
2 patients
standard-dose test, 420 nmol/L peak cutoff
Adrenal insufficiency proportion
8.7%
standard-dose test, 420 nmol/L peak cutoff
Source sentences
Summary
Using a peak total cortisol cutoff level of 420 nmol/L and increments of 200 μg above basal cortisol, AI was demonstrated in 5 patients (21.7%) after the LD ACTH and in 2 patients after SD ACTH test (8.7%), but none of controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188204
05HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, low-dose and standard-dose peak cortisol responses correlated (r = 0.83, P < 0.0001).
In plain wordsIn thalassemia patients, low-dose and standard-dose cortisol responses correlated.
Peptide
Cosyntropin
Outcome
Not applicableCorrelation between diagnostic doses
Study
n = 23
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Correlation coefficient
0.83
low-dose versus standard-dose peak cortisol, all patients
P
< 0.0001
correlation
Source sentences
Summary
Peak cortisol response to LD ACTH was correlated significantly with peak cortisol response to SD in all patients (r = 0.83, P < 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188211
06HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In healthy controls, neither low-dose nor standard-dose testing identified adrenal insufficiency using a 550 nmol/L peak cutoff and 200 μg increment above baseline.
In plain wordsIn healthy controls, neither cosyntropin dose identified adrenal insufficiency with the 550 nmol/L cutoff and the reported increment criterion.
Peptide
Cosyntropin
Outcome
Not applicableAdrenal insufficiency in controls at the 550 nmol/L cutoff
Study
n = 13
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
Using a peak total cortisol cutoff level of 550 nmol/L and increments of 200 μg above basal cortisol, adrenal insufficiency (AI) was demonstrated in 8 patients (34.7%) after the LD ACTH and in 2 patients (8.7%) after SD cosyntropin (ACTH) test, but none of the controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ci…
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188214
07HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In healthy controls, neither low-dose nor standard-dose testing identified adrenal insufficiency using a 420 nmol/L peak cutoff and 200 μg increment above baseline.
In plain wordsIn healthy controls, neither cosyntropin dose identified adrenal insufficiency with the 420 nmol/L cutoff and the reported increment criterion.
Peptide
Cosyntropin
Outcome
Not applicableAdrenal insufficiency in controls at the 420 nmol/L cutoff
Study
n = 13
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
Using a peak total cortisol cutoff level of 420 nmol/L and increments of 200 μg above basal cortisol, AI was demonstrated in 5 patients (21.7%) after the LD ACTH and in 2 patients after SD ACTH test (8.7%), but none of controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ci…
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188215
08HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, low-dose peak cortisol was lower with impaired than normal adrenal function: 294 ± 51 versus 454 ± 79.7 nmol/L.
In plain wordsIn thalassemia patients, low-dose peak cortisol was lower with impaired adrenal function than with normal adrenal function.
Peptide
Cosyntropin
Outcome
DecreaseLow-dose peak cortisol in impaired versus normal adrenal function
Study
n: not reported in source
Comparator
Thalassemia patients with normal adrenal function
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Peak cortisol
294 nmol/L
impaired adrenal function, low dose (1 μg)
Reported variability
51 nmol/L
impaired adrenal function, low dose (1 μg)
Peak cortisol
454 nmol/L
normal adrenal function, low dose (1 μg)
Reported variability
79.7 nmol/L
normal adrenal function, low dose (1 μg)
Source sentences
Summary
The peak cortisol concentrations in thalassemic patients with impaired adrenal function both after 1 μg and 250 μg cosyntropin (294 ± 51 nmol/L and 307 ± 58.6) were significantly lower than those with patients with normal (454 ± 79.7 nmol/L and 546.1 ± 92.2 nmol/L, respectively) and controls (460.2…
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188205
09HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients with impaired adrenal function, low-dose peak cortisol was lower than controls: 294 ± 51 versus 460.2 ± 133.4 nmol/L.
In plain wordsLow-dose peak cortisol was lower in thalassemia patients with impaired adrenal function than in controls.
Peptide
Cosyntropin
Outcome
DecreaseLow-dose peak cortisol in impaired function versus controls
Study
n: not reported in source
Comparator
Controls
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Peak cortisol
294 nmol/L
impaired adrenal function, low dose (1 μg)
Reported variability
51 nmol/L
impaired adrenal function, low dose (1 μg)
Peak cortisol
460.2 nmol/L
controls, low dose (1 μg)
Reported variability
133.4 nmol/L
controls, low dose (1 μg)
Source sentences
Summary
The peak cortisol concentrations in thalassemic patients with impaired adrenal function both after 1 μg and 250 μg cosyntropin (294 ± 51 nmol/L and 307 ± 58.6) were significantly lower than those with patients with normal (454 ± 79.7 nmol/L and 546.1 ± 92.2 nmol/L, respectively) and controls (460.2…
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188206
10HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients, standard-dose peak cortisol was lower with impaired than normal adrenal function: 307 ± 58.6 versus 546.1 ± 92.2.
In plain wordsIn thalassemia patients, standard-dose peak cortisol was lower with impaired adrenal function than with normal adrenal function.
Peptide
Cosyntropin
Outcome
DecreaseStandard-dose peak cortisol in impaired versus normal adrenal function
Study
n: not reported in source
Comparator
Thalassemia patients with normal adrenal function
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Peak cortisol
307 nmol/L
impaired adrenal function, standard dose (250 μg)
Reported variability
58.6 nmol/L
impaired adrenal function, standard dose (250 μg)
Peak cortisol
546.1 nmol/L
normal adrenal function, standard dose (250 μg)
Reported variability
92.2 nmol/L
normal adrenal function, standard dose (250 μg)
Source sentences
Summary
The peak cortisol concentrations in thalassemic patients with impaired adrenal function both after 1 μg and 250 μg cosyntropin (294 ± 51 nmol/L and 307 ± 58.6) were significantly lower than those with patients with normal (454 ± 79.7 nmol/L and 546.1 ± 92.2 nmol/L, respectively) and controls (460.2…
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188207
11HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In thalassemia patients with impaired adrenal function, standard-dose peak cortisol was lower than controls: 307 ± 58.6 versus 554.3 ± 165.8.
In plain wordsStandard-dose peak cortisol was lower in thalassemia patients with impaired adrenal function than in controls.
Peptide
Cosyntropin
Outcome
DecreaseStandard-dose peak cortisol in impaired function versus controls
Study
n: not reported in source
Comparator
Controls
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Peak cortisol
307 nmol/L
impaired adrenal function, standard dose (250 μg)
Reported variability
58.6 nmol/L
impaired adrenal function, standard dose (250 μg)
Peak cortisol
554.3 nmol/L
controls, standard dose (250 μg)
Reported variability
165.8 nmol/L
controls, standard dose (250 μg)
Source sentences
Summary
The peak cortisol concentrations in thalassemic patients with impaired adrenal function both after 1 μg and 250 μg cosyntropin (294 ± 51 nmol/L and 307 ± 58.6) were significantly lower than those with patients with normal (454 ± 79.7 nmol/L and 546.1 ± 92.2 nmol/L, respectively) and controls (460.2…
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188208
12HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In adolescents and young adults with thalassemia, standard-dose peak cortisol was significantly lower than controls.
In plain wordsIn adolescents and young adults with thalassemia, standard-dose peak cortisol was lower than in controls.
Peptide
Cosyntropin
Outcome
DecreaseStandard-dose peak cortisol in adolescents and young adults
Study
n: not reported in source
Comparator
Controls
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
Adolescents and young adults, but not children with thalassaemia, had significantly lower peak cortisol concentration after SD ACTH versus controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188209
13HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In children with thalassemia, standard-dose peak cortisol was not significantly lower than controls.
In plain wordsIn children with thalassemia, standard-dose peak cortisol was not significantly lower than in controls.
Peptide
Cosyntropin
Outcome
No significant changeStandard-dose peak cortisol in children
Study
n: not reported in source
Comparator
Controls
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
Adolescents and young adults, but not children with thalassaemia, had significantly lower peak cortisol concentration after SD ACTH versus controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188210
14HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In adolescents and young adults with thalassemia, DHEA-S after low-dose stimulation was significantly lower than controls.
In plain wordsAfter low-dose stimulation, DHEA-S was lower in adolescents and young adults with thalassemia than in controls.
Peptide
Cosyntropin
Outcome
DecreasePost-low-dose DHEA-S
Study
n: not reported in source
Comparator
Controls
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
In adolescents and young adults with thalassemia, DHEA-S levels before and after LD ACTH stimulation were significantly lower and the cortisol/DHEA-S ratios were significantly higher than the controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188212
15HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In adolescents and young adults with thalassemia, cortisol/DHEA-S ratios were significantly higher than controls (reported with low-dose ACTH stimulation).
In plain wordsIn adolescents and young adults with thalassemia, cortisol/DHEA-S ratios were higher than in controls.
Peptide
Cosyntropin
Outcome
IncreaseCortisol/DHEA-S ratio
Study
n: not reported in source
Comparator
Controls
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
In adolescents and young adults with thalassemia, DHEA-S levels before and after LD ACTH stimulation were significantly lower and the cortisol/DHEA-S ratios were significantly higher than the controls.
3 context sentences(design, population, supporting numbers)
Summary · context
We examined the adrenocortical function in 23 thalassemic patients (10 children and 13 young adults) aged 8-26 years.
Summary · context
Serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) concentrations were determined in each subject before blood transfusion both in basal condition and after low dose (LD) (1 μg), followed by standard dose (SD) (250 μg, respectively) with synthetic corticotrophin beta 1-24 ACTH (Synacthen, Ciba).
Summary · context
Normal controls were a group of 13 age- and sex-matched normal subjects.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-2438188213

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.